Clinical Trials on Inclusion Conjunctivitis in Mexico

Total 32 results

Laboratorios Sophia S.A de C.V.

Withdrawn

Efficacy and Safety of PRO-118 Ophthalmic Solution in Allergic Conjunctivitis (PRO-118)

Conjunctivitis, Allergic | Seasonal Allergic Conjunctivitis | Ocular Itching | Ocular Allergy | Perennial Allergic Conjunctivitis

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin) (Pazufloxacin)

Bacterial Conjunctivitis

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Clinical Trial to Compare the Safety and Efficacy of Nanodrop® (PRO-176/I)

Dry Eye

Mexico
Laboratorios Sophia S.A de C.V.

Recruiting

Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.

Bacterial Conjunctivitis | Ophthalmological Agent Toxicity

Mexico
Laboratorios Sophia S.A de C.V.

Terminated

Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%. (PRO-157)

Conjunctivitis, Bacterial

Mexico
Instituto Nacional de Cardiologia Ignacio Chavez

Completed

Distal Radial Artery Approach to Prevent Radial Artery Occlusion (DAPRAO) (DAPRAO)

Radial Artery Occlusion

Mexico
Instituto Nacional de Cardiologia Ignacio Chavez

Recruiting

Standard vs High Dose of Unfractionated Heparin in the Incidence of Radial Artery Occlusion (DEFINITION) Trial. (DEFINITION)

Radial Artery Occlusion

Mexico
Asociación para Evitar la Ceguera en México

Unknown

The Effect of Transcorneal Stimulation in Cases of Central Retinal Artery Occlusion Using a New Waveform

Central Retinal Artery Occlusion

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the PRO-174 Versus Sophixín Ofteno®, on the Ocular Surface of Healthy Subjects (PRO-174/I)

Conjunctivitis | Conjunctivitis, Bacterial

Mexico
Laboratorios Sophia S.A de C.V.

Withdrawn

Safety and Tolerability of PRO-143 Ophthalmic Solution in Healthy Volunteers. (PRO-143)

Conjunctivitis, Bacterial

Mexico
National Heart Institute, Mexico

Unknown

Prevention of Radial Artery Occlusion: Comparison of Three HEmostatiC Methods in Transradial Intervention (PROTHECT)

Complication | Occlusion of Artery | Radial Artery Injury

Mexico
Instituto de Oftalmología Fundación Conde de Valenciana

Completed

Liposomal Sirolimus in Dry Eye Disease

Dry Eye

Mexico
Asociación para Evitar la Ceguera en México

Unknown

Treatment of Bevacizumab and Triamcinolone in Treatment or Macular Edema Secondary to CRVO (MECROV)

Central Retinal Vein Occlusion | Macular Edema

Mexico
Oyster Point Pharma, Inc.

Completed

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

Dry Eye Disease

Mexico
Asociación para Evitar la Ceguera en México

Unknown

Bevacizumab and Retinal Vascular Occlusions

Vascular Occlusion | Edema Macular

Mexico
Eximore Ltd.

Active, not recruiting

Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B

Ocular Inflammation | Dry Eye | Keratoconjunctivitis Sicca

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-148 Versus Systane®, in Patients With Mild to Moderate Dry Eye

Dry Eye

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease. (PRO-037)

Dry Eye

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Phase IV Clinical Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye. (PRO-087)

Dry Eye

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Efficacy and Safety of PRO-148 Ophthalmic Solution Versus SYSTANE® in the Treatment of Patients With Dry Eye Syndrome (PRO-148)

Dry Eye Syndrome

Mexico
Instituto de Oftalmología Fundación Conde de Valenciana

Completed

Effect of Trigeminal Nerve Stimulation on Corneal Nerves and Chronic Ocular Pain

Dry Eye | Neuropathic Pain | Eye Pain

Mexico
Laboratorios Sophia S.A de C.V.

Completed

Safety and Tolerability of the Ophthalmic Gel PRO-167 Versus Corneregel® on Healthy Subjects. (PRO-167/I)

Dry Eye | Dry Eye Syndrome of Unspecified Lacrimal Gland

Mexico
Bayer

Completed

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice (MAIA)

Retinal Disease

Mexico
Adolfo Daniel Rodriguez-Carrizalez
Hospital Civil de Guadalajara

Recruiting

Effect of Topical Antioxidants in Dry Eye Disease and Diabetic Retinopathy

Diabetic Retinopathy | Dry Eye Syndromes | Oxidative Stress | Tear Film Deficiency

Mexico
Circassia Limited
inVentiv Health Clinical; Pharm-Olam International

Completed

Phase III Cat-PAD Study

Rhinoconjunctivitis

United States, Poland, Germany, Belgium, Canada, Russian Federation, Hungary, Slovakia, Czechia
Otsuka Pharmaceutical Development & Commercialization...
Novartis

Completed

Study of Rebamipide Eye Drops to Treat Dry Eye

Keratoconjunctivitis Sicca

United States
Allergan

Completed

A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion

Macular Edema | Retinal Vein Occlusion

France, United States, Canada, Taiwan, Australia, Austria, Czechia, Portugal, Germany, Israel, Philippines, Mexico, South Africa
Outlook Therapeutics, Inc.

Completed

A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders

Age-related Macular Degeneration | Diabetic Macular Edema | Wet Macular Degeneration | Neovascular Age-related Macular Degeneration | BRVO - Branch Retinal Vein Occlusion

United States
LimFlow, Inc.

Active, not recruiting

PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia (PROMISE)

Vascular Diseases | Arterial Occlusive Diseases | Peripheral Arterial Disease | Peripheral Vascular Disease | Peripheral Artery Disease | Critical Limb Ischemia | Arterial Disease | Arterial Occlusion | Critical Lower Limb Ischemia | Chronic Limb-Threatening Ischemia | Peripheral Artery Occlusion | Peripheral...

United States, Puerto Rico
Abbott Medical Devices

Completed

SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)

Myocardial Ischemia | Coronary Artery Disease | Stent Thrombosis | Vascular Disease | Coronary Artery Stenosis | Stents | Total Coronary Occlusion | Coronary Artery Restenosis

United States
Bayer
Regeneron Pharmaceuticals

Recruiting

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion) (QUASAR)

Macular Edema Secondary to Retinal Vein Occlusion

Japan, Korea, Republic of, China, Israel, Lithuania, United States, Italy, Spain, Hungary, Portugal, Serbia, Poland, United Kingdom, Thailand, Czechia, Austria, Germany, Turkey, Australia, Bulgaria, Estonia, France, Georgia, Latvia, Mal... and more
Novartis Pharmaceuticals

Completed

Observe the Effectiveness and Safety of Ranibizumab in Real Life Setting (LUMINOUS)

Diabetic Macular Edema | Retinal Vein Occlusion | Wet Age Related Macular Degeneration | Wet Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion

Spain, China, Colombia, Korea, Republic of, Belgium, Greece, Japan, Russian Federation, Turkey, United Kingdom, Egypt, Germany, Australia, Canada, France, Austria, Hong Kong, Hungary, Israel, Netherlands, Peru, Singapore, Slovakia, Sl... and more

Clinical Trials on Inclusion Conjunctivitis in Mexico

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations